What does a low AMH result actually mean?

A low AMH suggests a lower ovarian reserve — fewer eggs available. It does not predict whether or when you will conceive naturally. Research consistently shows AMH levels are not linked to the chance or timing of natural pregnancy. The test is most useful in an IVF setting, where it helps estimate egg yield per stimulated cycle.

Should I get an AMH test to check my fertility?

Unless you are already in a fertility investigation, an AMH test is unlikely to give you useful information about your natural fertility. Age is a much stronger factor. If fertility is a concern, speak to your GP — they can assess the full picture rather than a single hormone value, and refer you appropriately if needed.

The egg-timer test is rising fast. Here's what it can't tell you

Something shifted quietly in Australian reproductive health over the last decade. Between 2011 and 2021, the AMH (anti-Müllerian hormone) test — commonly sold to the public as an “egg-timer” for fertility — rose more than 13-fold among Australian women, according to new research from Flinders University analysing health records from almost 1.4 million women. Women aged 30 to 34 saw the sharpest growth: a nearly 20-fold rise. One in five women who took the test received a low result.

Those are large numbers. They arrive with a troubling backdrop: the evidence consistently shows that AMH levels are not reliably linked to a woman’s chance of conceiving naturally, or to how long it might take.

What the test actually measures

AMH is produced by cells in the ovarian follicles. A blood AMH level gives a rough estimate of ovarian reserve — broadly, how many eggs remain in the pipeline. In IVF settings, the test has clear utility: it helps clinicians estimate how many eggs might be retrieved in a stimulated cycle, and flags the risk of ovarian hyperstimulation syndrome in women with very high levels. Those are real clinical applications for which the test was designed.

The test does not assess egg quality. It does not predict fertility. It does not estimate time-to-pregnancy. This is not a minor caveat buried in fine print. The evidence cited in the Flinders study is consistent: AMH is not a useful predictor of natural conception. Yet women are making significant life decisions — rescheduling careers, pursuing egg freezing, entering IVF — based on a low AMH result obtained entirely outside a clinical investigation process. The test is not Medicare-rebated and typically costs over $100 out of pocket.

A number that doesn’t hold still

The Flinders study adds a finding that deserves attention in its own right. Among women who repeated the test after an initial low result, approximately one in three had a normal result on the second test. A hormone level that says “low” and then “normal” is doing a poor job as a clinical decision-making tool — particularly when women are rearranging their reproductive plans around the first reading.

Professor Karin Hammarberg from Monash University describes a “snowball effect”: a low AMH triggers anxiety, anxiety drives a referral, and the referral leads to costly and emotionally taxing interventions that may not have been necessary. University of Sydney researcher Tessa Copp points to social media and commercial fertility clinics as amplifiers of messaging not supported by the evidence base behind it. She has used the phrase “false and misleading information” about how the test is being promoted to the public.

The other edge cuts in the opposite direction. A high AMH result can produce false reassurance — a sense that there are “plenty of eggs” and no urgency to plan. But egg quality, which declines reliably with age and cannot be measured by a blood test, matters as much as egg quantity. A woman who reads a reassuring AMH result at 36 and concludes she has comfortable time to delay pregnancy may not be interpreting what the test can actually tell her.

What the evidence does support

Age is the most reliable indicator of fertility potential. Fertility declines gradually rather than suddenly at 35, but the cumulative effect across the late 30s and early 40s is real and clinically significant. Lifestyle factors — body weight, smoking, alcohol intake, cycle regularity — contribute meaningfully and remain modifiable.

Lead researcher Luke Grzeskowiak from Flinders University has called for better education for both clinicians and the public about the limits of AMH testing. That gap is real. When a woman arrives at a general practice consultation having already paid for a test based on social media encouragement, the clinical task is to carefully contextualise what the number means — and what it cannot tell her. That work is better done with the result in hand than by refusing to engage with a number already driving decisions.

The Australian government’s Your Fertility resource provides free, factual information about fertility and age, including guidance on when to seek help if trying to conceive and what factors actually matter. It is a useful starting point for women who want reliable information before deciding whether any testing is appropriate.

2 cents

If you have received a low AMH result — from a private clinic, a general practice, or a direct-to-consumer service — and it has been driving worry or plans, the most useful step is a conversation with your GP. Not to dismiss the result, but to place it in its correct clinical frame: one data point, useful in a specific context, with known variability, and unable to answer the question most women are actually asking.

The 13-fold rise in AMH testing without a corresponding improvement in fertility outcomes tells us something. It tells us that a number that feels like certainty is being marketed — by social media, by commercial clinics, and sometimes by clinical systems without clear safeguards — in a space where certainty is genuinely not available.

Your fertility is not a number on a single blood test. It is a conversation with someone who can look at the whole picture.

Verdict: yes — worth knowing about. The AMH test has real clinical value in fertility treatment planning; it should not be driving life decisions outside that context.